Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.06 USD | +0.49% | -6.79% | -70.66% |
Business Summary
Number of employees: 19
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Inhaled Dry Powder Drugs
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +48.02% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States and Australia
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +48.02% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Harlan Weisman
CEO | Chief Executive Officer | 71 | 18-11-30 |
Kirk Coleman
DFI | Director of Finance/CFO | 51 | 18-01-23 |
Zamaneh Mikhak
CTO | Chief Tech/Sci/R&D Officer | 58 | 23-01-08 |
Chief Tech/Sci/R&D Officer | - | - | |
Robert Mills
BRD | Director/Board Member | 71 | 18-01-23 |
John J. Koleng
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 18-11-30 | |
Brandi Roberts
BRD | Director/Board Member | 50 | 22-03-24 |
Thomas King
BRD | Director/Board Member | 69 | Dec. 12 |
Robert Mills
BRD | Director/Board Member | 71 | 18-01-23 |
Harlan Weisman
CEO | Chief Executive Officer | 71 | 18-11-30 |
Catherine C. Lee
BRD | Director/Board Member | 50 | Nov. 29 |
Michael Patane
BRD | Director/Board Member | 59 | Nov. 29 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,098,134 | 3,011,381 ( 97.20 %) | 0 | 97.20 % |
Company contact information
TFF Pharmaceuticals, Inc.
1751 River Run Suite 400
76107, Fort Worth
+817 438 6168
http://www.tffpharma.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-70.66% | 6.38M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- TFFP Stock
- Company TFF Pharmaceuticals, Inc.